glp-1 physiology informs the pharmacotherapy of obesity pharmacotherapy: incretin action in central nervous system: Trends in Pharmacological Sciences Targeting Obesity: GLP-1R, GIPR, GDF8

Name: glp-1 physiology informs the pharmacotherapy of obesity pharmacotherapy: incretin action in central nervous system: Trends in Pharmacological Sciences Targeting Obesity: GLP-1R, GIPR, GDF8
Brand: buntepalette-gmbh.de
SKU: 77704152969
Price: 21.42 USD
Availability: InStock
Rating: 4.5445 (22 reviews)

SKU: 77704152969

4.5

EUR21.42 EUR68.42

Pay in 4 interest-free payments of $5.36 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 1 - Aug 6

Live Spec

Targeting Obesity: GLP 1R, GIPR, GDF8 as Key Therapeutic Agents KACTUS glp 1 physiology informs the pharmacotherapy of obesity Bridging the gap between GLP1 receptor agonists and cardiovascular outcomes: evidence for the Pharmacotherapy for obesity managementEmphasizing the role of GLP 1 receptor agonist based therapeutics ScienceDirect Oral Treatment of Obesity by GLP 1 and Its Analogs

Store: buntepalette-gmbh.de · Domain: buntepalette-gmbh.de

Description

[15] [16] For patients on GLP-1 medications, maintaining electrolyte balance becomes especially important for several reasons

GPER can inhibit the activity of the branched-chain -ketoacid dehydrogenase complex (BCKDH), leading to the accumulation of branched-chain amino acids within cells